LBA32 - Encorafenib plus cetuximab with or without binimetinib for BRAF V600E–mutant metastatic colorectal cancer: Expanded results from a randomized, 3-arm, phase III study vs the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC)

Josep Tabernero ,Fortunato Ciardiello ,Lisa R Anderson ,Éric Van Cutsem ,Ashwin Gollerkeri ,Tormod Kyrre Guren ,Neeltje Steeghs ,Jayesh Desai ,Takayuki Yoshino ,Axel Grothey ,Pilar García‐Alfonso ,H-T Arkenau ,Harpreet Wasan ,Janna Christy‐Bittel ,Kati Maharry ,Fotios Loupakis ,Rona Yaeger ,Michael D Pickard ,Yong Sang Hong ,Scott Kopetz

doi:10.1093/annonc/mdz394.021

LBA32 - Encorafenib plus cetuximab with or without binimetinib for BRAF V600E–mutant metastatic colorectal cancer: Expanded results from a randomized, 3-arm, phase III study vs the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC)

Josep Tabernero , Fortunato Ciardiello + Show 18 more

Open Access

https://doi.org/10.1093/annonc/mdz394.021

Copy DOI

Journal: Annals of Oncology	Publication Date: Oct 1, 2019
Citations: 4	License type: elsevier-specific: oa user license

Affiliation: Vall d'Hebron Hospital Universitari, University of Campania "Luigi Vanvitelli", Pfizer (United States), KU Leuven, Oslo University Hospital, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Peter MacCallum Cancer Centre, National Cancer Center Hospital East, West Cancer Center, Hospital General Universitario Gregorio Marañón, Sarah Cannon Research Institute, Hammersmith Hospital, Imperial College London, Istituti di Ricovero e Cura a Carattere Scientifico, Istituto Oncologico Veneto, Memorial Sloan Kettering Cancer Center, Asan Medical Center, The University of Texas MD Anderson Cancer Center

#Research Grant #Funding Institution + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

LBA32 - Encorafenib plus cetuximab with or without binimetinib for BRAF V600E–mutant metastatic colorectal cancer: Expanded results from a randomized, 3-arm, phase III study vs the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC)

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.